Abivax SA
ABVX105.270USD
+1.370+1.32%
종가 11/07, 16:00（ET）시세는 15분 지연됩니다
0.00시가총액
--P/E TTM
자세한 내용은 Abivax SA 회사
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA 정보
종목 코드 ABVX
회사 이름Abivax SA
상장일Jun 26, 2015
CEOMr. Marc De Garidel
직원 수- -
유형Ordinary Share
회계 연도 종료- -
주소7-11 Boulevard Haussmann
도시PARIS
증권 거래소Euronext Paris
국가France
우편 번호75009
전화33153830963
웹사이트https://www.abivax.com/
종목 코드 ABVX
상장일Jun 26, 2015
CEOMr. Marc De Garidel
Abivax SA의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mary Mantock
Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Mr. Patrick Malloy
Mr. Patrick Malloy
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
,
,
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Kevin Shan
Kevin Shan
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Ms. Sophie Lacourrege
Ms. Sophie Lacourrege
Vice President, HR Business Partner, Engagement and Culture
Vice President, HR Business Partner, Engagement and Culture
--
--
Nadege Briancon-eris
Nadege Briancon-eris
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Jennifer Fine
Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Douglas Jacobstein
Douglas Jacobstein
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Nov 8
마지막 업데이트: Sat, Nov 8
주주
주주 유형
주주
주주
비율
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
기타
77.69%
주주
주주
비율
TCG Crossover Management, LLC
8.23%
Deep Track Capital LP
4.73%
Adar1 Capital Management LLC
4.17%
Cormorant Asset Management, LP
2.90%
Caligan Partners, LP
2.28%
기타
77.69%
주주 유형
주주
비율
Hedge Fund
24.85%
Investment Advisor
12.52%
Investment Advisor/Hedge Fund
6.12%
Venture Capital
1.86%
Research Firm
0.89%
기타
53.77%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
120
34.39M
46.74%
-4.46M
2025Q2
74
31.84M
43.27%
-317.11K
2025Q1
74
31.82M
50.18%
-39.44K
2024Q4
67
29.91M
47.53%
+1.67M
2024Q3
53
27.43M
43.59%
-1.47M
2024Q2
50
28.12M
44.69%
-980.96K
2024Q1
45
23.37M
37.15%
+1.78M
2023Q4
32
21.64M
34.39%
+20.54M
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
TCG Crossover Management, LLC
6.06M
8.23%
--
--
Jun 30, 2025
Deep Track Capital LP
3.48M
4.73%
-99.06K
-2.77%
Jun 30, 2025
Adar1 Capital Management LLC
3.07M
4.17%
+861.32K
+38.97%
Jun 30, 2025
Cormorant Asset Management, LP
2.13M
2.9%
--
--
Jun 30, 2025
Caligan Partners, LP
1.67M
2.28%
+405.28K
+31.93%
Jun 30, 2025
Nantahala Capital Management, LLC
1.48M
2.02%
--
--
Jun 30, 2025
Franklin Advisers, Inc.
1.37M
1.86%
--
--
Jun 30, 2025
VR Adviser, LLC
1.35M
1.83%
--
--
Jun 30, 2025
Great Point Partners, LLC
1.29M
1.76%
-346.49K
-21.15%
Jun 30, 2025
Octagon Capital Advisors LP
1.27M
1.72%
+37.00K
+3.01%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Thu, Nov 6
마지막 업데이트: Thu, Nov 6
이름
비율
Simplify Health Care ETF
4.12%
Fidelity Nasdaq Composite Index ETF
0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
0%
Innovator IBD Breakout Opportunities ETF
0%
Simplify Health Care ETF
비율4.12%
Fidelity Nasdaq Composite Index ETF
비율0.01%
First Trust Multi-Manager Small Cap Opportunities ETF
비율0%
Innovator IBD Breakout Opportunities ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
